Clinical Trials
14 trialsNCT06663319 2026-05-08
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05489237 2026-05-04
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1 Recruiting
NCT07544589 2026-04-27
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Dispatch Biotherapeutics
Phase 1 Recruiting
NCT04847063 2026-04-14
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT07337525 2026-02-18
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences Inc
Phase 1 Recruiting
NCT07329894 2026-02-12
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT07319364 2026-01-06
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
NCT06375187 2025-12-11
KUNLUN-001
Shanghai Juncell Therapeutics
Phase 1 Recruiting
NCT05274048 2025-10-29
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
Phase 1 Recruiting
NCT06040541 2025-08-28
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Recruiting
NCT06414733 2025-08-24
HER-2 B Cell Peptide Vaccine
Indiana University
Phase 1 Recruiting
NCT06012734 2024-08-30
CoLBAt
The Netherlands Cancer Institute
Phase 1 Recruiting